Valuation: Celsion Corporation

Market Cap 7.69M 6.72M 6.2M 5.72M 10.77M 741M 11.01M 74.12M 29.15M 363M 28.88M 28.25M 1.25B P/E 2026 *
-0.59x
P/E 2027 * -0.8x
Enterprise Value 7.69M 6.72M 6.2M 5.72M 10.77M 741M 11.01M 74.12M 29.15M 363M 28.88M 28.25M 1.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-7.17%-4.39%+45.51%+79.00% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+168.44%+306.37% 16.09B
-6.91%-5.83%+26.53%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -2.77%-0.13%+40.77%+183.80% 26.72B
Weighted average by Cap. -2.92%-0.73%+40.59%+144.79%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.34M -13.23M -12.2M -22.99M -1.58B -23.5M -158M -62.2M -774M -61.62M -60.27M -2.66B -23.33M -20.39M -18.81M -17.34M -32.68M -2.25B -33.41M -225M -88.44M -1.1B -87.61M -85.68M -3.79B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-